The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses

被引：0
|
作者：
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Amancherla, Kaushik [1 ]
Camacho, Cristel [1 ]
Burma, Sandeep [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3745
引用
收藏
页数：2
相关论文
共 50 条
  • [41] NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells
    Serra, Violeta
    Eichhorn, Pieter
    Scaltriti, Maurizio
    Prudkin, Ludmila
    Rodriguez, Olga
    Guzman, Marta
    Baselga, Jose
    CANCER RESEARCH, 2009, 69
  • [42] Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
    Li, Jie
    Wang, Xiaozi
    Ma, Chuanbao
    Xu, Shasha
    Xu, Mengyao
    Yang, Jie
    Wang, Ruicang
    Xue, Liying
    MOLECULAR MEDICINE REPORTS, 2021, 23 (04)
  • [43] The combination of gemcitabine with the dual PI3K/mTOR-inhibitor NVP-BEZ235 in human pancreatic cancer cell lines
    Glienke, W.
    Hausmann, E.
    Wicht, J.
    Maute, L.
    Bergmann, L.
    ONKOLOGIE, 2011, 34 : 57 - 58
  • [44] Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Oda, K.
    Shoji, K.
    Nakagawa, S.
    Kashiyama, T.
    Ikeda, Y.
    Miyamoto, Y.
    Tanikawa, M.
    Kuramoto, H.
    Nishida, M.
    Hiraike-Wada, O.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Discovery of NVP-BEZ235 - A dual PI3K/mTOR inhibited for targeted cancer treatment
    Garcia-Echeverria, Carlos
    JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (07) : 697 - 698
  • [46] Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model
    Matsushima, Masashi
    Kikuchi, Eiji
    Matsumoto, Kazuhiro
    Hattori, Seiya
    Takeda, Toshikazu
    Kosaka, Takeo
    Miyajima, Akira
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 377 - 383
  • [47] The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
    Zhang, Chang-Hua
    Awasthi, Niranjan
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (05) : 1627 - 1635
  • [48] Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
    Kuger, Sebastian
    Graus, Dorothea
    Brendtke, Rico
    Guenther, Nadine
    Katzer, Astrid
    Lutyj, Paul
    Polat, Buelent
    Chatterjee, Manik
    Sukhorukov, Vladimir L.
    Flentje, Michael
    Djuzenova, Cholpon S.
    TRANSLATIONAL ONCOLOGY, 2013, 6 (02): : 169 - U243
  • [49] The PI3K/mTOR inhibitor NVP-BEZ235 is able to revert selumetinib resistance in colorectal cancer cellular models
    Martinez-Lacaci, I.
    Carballo-Santana, M.
    Tristante, E.
    Mayor-Lopez, L.
    Grasso, S.
    Carbonell, P.
    De Torre, C.
    Lujan, J.
    Alonso, J. L.
    Carballo, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S195 - S195
  • [50] Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia
    Liu, Hongtao
    Diaz-Flores, Ernesto
    Poire, Xavier
    Odenike, Olatoyosi
    Koval, Greg
    Malnassy, Greg
    Ihonor, Pamela
    Zhang, Yanming
    Le Beau, Michelle M.
    Sharinon, Kevin
    Stock, Wendy
    BLOOD, 2010, 116 (21) : 1622 - 1622
12345